• Immatics N.V. has released its first-quarter 2026 results, reporting a net loss of €57.81 million, with basic and diluted loss per share from continuing operations of €0.43, compared with €0.33 in the prior-year period.
• The widening loss suggests higher spending or lower income across Immatics’ operations, which may influence how investors view its ability to fund ongoing development.
• With earnings pointing to a wider net loss, we’ll examine how this affects Immatics’ investment narrative and expectations around future cash needs.

The latest GPUs need a type of rare earth metal called Dysprosium and there are only 28 companies in the world exploring or producing it. Find the list for free.

What Is Immatics' Investment Narrative?

To be comfortable owning Immatics, you really have to believe in its TCR and TCER platforms translating promising early data, like the recent pediatric PRAME case and IMA203 response rates, into approved products over time. The story is still about science and optionality rather than profits, which the latest quarter underlines with a wider €57.81 million loss and higher loss per share. That result does not appear to change the near term clinical catalysts, such as further IMA203 updates and progress on the SUPRAME Phase 3 program, but it does sharpen the focus on funding risk, especially given the company’s rich price to sales multiple and history of follow on equity raises. Put simply, the latest numbers keep the science intact while making the cash question harder to ignore.

However, one risk investors should not overlook is how further cash needs might affect their stake. The analysis detailed in our Immatics valuation report hints at an inflated share price compared to its estimated value.

Exploring Other Perspectives

Three Simply Wall St Community fair value views span roughly €7 to €19 per share, underscoring how far opinions can diverge. Set that against rising losses and funding needs, and you may want to compare several perspectives before deciding what the current price really implies for Immatics’ future.

Explore 3 other fair value estimates on Immatics - why the stock might be worth 37% less than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Immatics research is our analysis highlighting 1 key reward and 1 important warning sign that could impact your investment decision.
• Our free Immatics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Immatics' overall financial health at a glance.

Want Some Alternatives?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.
• We've uncovered the 10 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.